Annovis Bio, Inc. (ANVS) |
| 1.66 0.07 (4.4%) 04-13 16:00 |
| Open: | 1.59 |
| High: | 1.7 |
| Low: | 1.55 |
| Volume: | 2,451,448 |
| Market Cap: | 33(M) |
| PE Ratio: | -1.68 |
| Exchange: | New York Stock Exchange |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 3.03 |
| Resistance 1: | 2.46 |
| Pivot price: | 2.11 |
| Support 1: | 1.54 |
| Support 2: | 1.29 |
| 52w High: | 5.5 |
| 52w Low: | 1.19 |
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Financials
| EPS | -1.400 |
| Book Value | 0.620 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -106.0 |
| Return on Equity (ttm) | -220.6 |
Company news
Fri, 10 Apr 2026
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission - ChartMill
Fri, 10 Apr 2026
A $10M cash boost puts Annovis on track for an Alzheimer’s drug filing - Stock Titan
Fri, 10 Apr 2026
Annovis Bio Secures ~$10 Million Underwritten Registered Direct Offering With Canaccord Genuity - TradingView — Track All Markets
Fri, 10 Apr 2026
Annovis Bio (ANVS) price target increased by 13.94% to 15.98 - MSN
Thu, 09 Apr 2026
Annovis Bio (ANVS) launches $10M stock and warrant offering for Phase 3 drug - Stock Titan
Thu, 09 Apr 2026
Annovis Bio stock tumbles 26% on dilutive equity offering - Investing.com
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
